[1] Limited Genetic Susceptibility to Severe Graves' Ophthalmopathy: No Role for CTLA-4 But Evidence for an Environmental Etiology

[2] Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study.

[3] The soluble isoform of CTLA-4 as a regulator of T-cell responses.

[4] CTLA4 message reflects pathway disruption in monogenic disorders and under therapeutic blockade

[5] Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations

[6] in vivo fluctuation of tax, foxp3, ctla-4, and gitr mrna expression in cd4+cd25+ t cells of patients with human t-lymphotropic virus type 1-associated myelopathy

[7] radiotherapy enhances responses of lung cancer to ctla-4 blockade

[8] opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-ctla-4 and anti-pd-1

[9] costimulatory blockade of the cd28 / cd80-86 / ctla-4 balance in transplantation: impact on memory t cells?

[10] anti-pd-1 and anti-ctla-4 therapies in cancer: mechanisms of action, efficacy, and limitations

[11] Limited Genetic Susceptibility to Severe Graves' Ophthalmopathy: No Role for CTLA-4 But Evidence for an Environmental Etiology